408 related articles for article (PubMed ID: 16024592)
1. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria.
Hadjivassileva T; Thurston DE; Taylor PW
J Antimicrob Chemother; 2005 Sep; 56(3):513-8. PubMed ID: 16024592
[TBL] [Abstract][Full Text] [Related]
2. Interactions of pyrrolobenzodiazepine dimers and duplex DNA from methicillin-resistant Staphylococcus aureus.
Hadjivassileva T; Stapleton PD; Thurston DE; Taylor PW
Int J Antimicrob Agents; 2007 Jun; 29(6):672-8. PubMed ID: 17350809
[TBL] [Abstract][Full Text] [Related]
3. Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers.
Gregson SJ; Howard PW; Gullick DR; Hamaguchi A; Corcoran KE; Brooks NA; Hartley JA; Jenkins TC; Patel S; Guille MJ; Thurston DE
J Med Chem; 2004 Feb; 47(5):1161-74. PubMed ID: 14971896
[TBL] [Abstract][Full Text] [Related]
4. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
5. Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers.
Griffin JH; Linsell MS; Nodwell MB; Chen Q; Pace JL; Quast KL; Krause KM; Farrington L; Wu TX; Higgins DL; Jenkins TE; Christensen BG; Judice JK
J Am Chem Soc; 2003 May; 125(21):6517-31. PubMed ID: 12785792
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria.
Kerns RJ; Rybak MJ; Cheung CM
Diagn Microbiol Infect Dis; 2006 Apr; 54(4):305-10. PubMed ID: 16466892
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species.
Farrell DJ; Robbins M; Rhys-Williams W; Love WG
Int J Antimicrob Agents; 2010 Jun; 35(6):531-6. PubMed ID: 20346634
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
11. DNA binding ligands targeting drug-resistant bacteria: structure, activity, and pharmacology.
Kaizerman JA; Gross MI; Ge Y; White S; Hu W; Duan JX; Baird EE; Johnson KW; Tanaka RD; Moser HE; Bürli RW
J Med Chem; 2003 Aug; 46(18):3914-29. PubMed ID: 12930152
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
Alhanout K; Brunel JM; Raoult D; Rolain JM
J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
[TBL] [Abstract][Full Text] [Related]
15. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
16. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
17. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
18. An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs.
Tiberghien AC; Evans DA; Kiakos K; Martin CR; Hartley JA; Thurston DE; Howard PW
Bioorg Med Chem Lett; 2008 Mar; 18(6):2073-7. PubMed ID: 18272367
[TBL] [Abstract][Full Text] [Related]
19. Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers.
Smellie M; Bose DS; Thompson AS; Jenkins TC; Hartley JA; Thurston DE
Biochemistry; 2003 Jul; 42(27):8232-9. PubMed ID: 12846572
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
